Omnicare, Inc. (NYSE:OCR)

A stock that has been hurt by health care reform and continued cuts by patient care facilities. In particular cost cuts in Medicare Part D. All that being said, this stock has been trading below book value and has continued to throw off huge growing cash flows (trading around 10x cash flow at present). What this company will lose in reduced patient care costs, it will gain in patient volumes over the years. There is some serious future potential for Omnicare. Recent management change is a plus and the company has recently been turning lemons into lemonade (it also services these patient care facilities as far as compliance relations.) Where's the Moat? Omnicare is the largest pharma service company in NA with a huge logistics and delivery operation. They offer compliance consulting, CRO services (for all stages of drug testing), and contract based pharmacy services. They also have a wide database of patient data. In these heavily regulated environments, this company is a necessity to most patient care facilities and will continue to prosper in a sector that has potential for huge growth.

Pharmaceutical management for healthcare service facilities. All these aging babyboomers provide a massive growing demand base.

Will benefit greatly from the Health care plan, plus undervalued.

4/12 screen #2: percentile and CS

I see so many old people shuffling about...

Being a sizable stockholder for 13 years I am certainly in hopes that it finally catches up with my cost (34.50) 13 years ago. Come on everybody buy some.

Good balance sheet and also good acquisition target.

net income growth by 37%

Well run company in a growing space that is on sale at incredible low price.

OCR will anooune its earning that historical has gowth in relative strength

health care

OCR will be one of the surprising 3 star stocks. current very undervalued IV of 54.00

pay a small dividend for your wait.

oh!! by the way america is getting OLDER!!!!!

old age more drugs, keep your cost down buy generic, equals OCR

Market reactions overblown. Capitalizing on long-term irreversable trend called "getting older". Americans don't want to take care of their own aging family members, so they will end up in assisted living with companies like OCR making a nice profit for related services.

love those monopolies

Looks way undervalued compared to historical P/E

market over-reacting to bad news. OCR will return to form and expect a nice bounce

Unwarranted fall, IV.

Entering during what I think is an overreaction to poor Q1 results. This leading company is in a field where aging boomers will be a driving factor for decades.

A near monopoly in institutional pharmecueticals. Top line growth along with margin improvement over the next 2 years. Problems of late are temporary, have nothing to do with long term viability of the business.